Serum Biochemical Parameters Harmonized with Demographic Characteristics in Bladder Cancer Patients

Abstract:
This study investigated variations
in biochemical parameters across different age groups, BMI categories, and
smoking status to assess metabolic health and disease risk. Key findings
include age-related trends; stable parameters: Total cholesterol (TC), HDL-C,
LDL-C, atherogenic index, urea, ALT, AST, total protein (TP), and albumin
showed no significant differences across age groups (under 50, 50–65, and over
65 years). Age-Dependent Changes Triglycerides (TG) and VLDL-C levels decreased
significantly with age, while creatinine levels increased significantly with
advancing age. BMI-Related Trends: Significant Increases TC and LDL-C levels
rose significantly with higher BMI (normal weight, overweight, obese). Stable
Parameters TG, HDL-C, VLDL-C, atherogenic index, urea, creatinine, ALT, and AST
showed no significant differences across BMI groups. Smoking-Related Trends: Smokers
exhibited trends of elevated levels in urea, creatinine, ALT, AST, TC, TG,
VLDL, and LDL compared to non-smokers, though none of these differences were
statistically significant. HDL was slightly lower, and total protein and
albumin showed minimal differences in smokers, none of which were statistically
significant. Age significantly influences TG, VLDL-C, and creatinine levels,
highlighting the importance of age-specific metabolic assessments. Higher BMI
is associated with adverse lipid profiles, particularly elevated TC and LDL-C,
emphasizing the need for weight management in cardiovascular health. Smoking
may impact biochemical parameters, but further research is required to confirm
these trends. These findings underscore the importance of considering age, BMI,
and lifestyle factors when evaluating metabolic health and disease risk.
References:
[1]. Nautiyal, M., Ganapathy, D., Ameya, K. P., Sekar, D.,
2024, Analysis of Carboplatin and STAT3 in the Breast Cancer MCF7 Cell Line. Texila
International Journal of Public Health, 12(2):1-10, doi:10.21522/TIJPH.2013.12.02.
Art026.
[2]. Ravikumar, L., Velmurugan, R., Hashvitha, P.,
Subhashini, K., Sheshan, A., Subburam, R., Gnanaprakash K., 2024, Flavonoid
Nanoparticles: Revolutionizing Cancer Treatment Strategies. Texila
International Journal of Public Health, 12(04):1-9, doi:10.21522/TIJPH.2013.12.04. Art051.
[3]. Thoke, G. M., Usman P, P., Ganapathy, D., Sekar, D., 2024,
Analysis of TGF-β Gene Expression in Carboplatin Treated Lung Cancer Cells. Texila
International Journal of Public Health,12(04):1-10, doi:10.21522/TIJPH.2013.12.04.
Art094.
[4]. Abed, W. T., Alabbas, E. A. K., Hawass, A. A., 2025,
Estimating of the Levels of Some Biochemical Variables, Adipokines and
Cytokines in Women with Polycystic Ovarian Syndrome. J Nat Sc Biol Med, 16(1):90–7. doi: 10.4103/jnsbm.JNSBM_16_1_10.
[5]. Rani, V., Amudha, P., Vidya, R., Jayalakshmi, M.,
Kalpana, C. S., 2024, Molecular Docking Analysis of 9-Octadecene,
9,12,15-Octadecatrienoic acid, Methyl Ester, Phytol, 9,12-Octadecadienoic Acid
and 9-Octadecenoic Acid with Anticancer Target Enzyme Caspase 3 (PDB: 1CP3). Texila
International Journal of Public Health, 12(04):1-14. doi:10.21522/TIJPH.2013.12.04. Art097.
[6]. Moulazadeh, A., Ranjbar, R., Kouhpayeh, S. A.,
Najafipour, S., 2024, The Effect of Different Polar Solvents on the Extraction
of Bioactive Compounds in Ferula assafoetida and Subsequent Cytotoxic Effects.
Physiology and Pharmacology, 28(4), 476-485. doi:10.61186/phypha.28.4.476.
[7]. Digala, P., Muthu, S., Subramani, N., Duraisamy, N.,
Sundararaj, D., 2024, Understand the Fatty Acid Metabolic Reprogramming of
Immune Cells in Colorectal Cancer. Texila International Journal of Public
Health, 12(3): 1-8, doi:10.21522/TIJPH.2013.12.03. Art017.
[8]. Mohammed, M. H., Mohammad, J. A., IZBA, S. H., 2025,
Serum Resistin, Vitamin D, and Vitamin E levels in Patients with Mild and
Moderate Psoriasis. J Nat Sc Biol Med, 16(1):75–81. doi: 10.4103/jnsbm.JNSBM_16_1_8.
[9]. Anbu, P., Vadhana, T. I. M., Saravanabhavan, S. S.,
Kumar, S. T., 2024, Nano-materials in Drug Delivery Systems for Oral Cancer
Treatment. Texila International Journal of Public Health, 12(3):1-6, doi:10.21522/TIJPH.2013.12.03. Art052.
[10]. Kumar, R. S., Amudha, P., Vidya, R., Kalpana, C. S.,
Sudhashini, S., 2024, A Review on Anticancer Properties of Chebulagic Acid from
Terminalia chebula. Texila International Journal of Public Health, 12(3): 1-12, doi:10.21522/TIJPH.2013.12.03. Art047.
[11]. Zbaar, S., Kamal, I., Alchalabi, A., 2024, Association
between serum levels of adipokines in patients with prostate cancer. Georgian
medical news, (357), 173-177.
[12]. Alsarraf, Z., Nori, A. Y., Oraibi, A. I., Al_hussaniy,
H. A., Jabbar, A. A., 2024, BIBR1591 induces apoptosis in breast cancer cell
line and increases expression of DAPK1, AND NR4A3. Cancer, 9, 11.
[13]. Matsumoto, Y., Hayashi, T., Amano, Y., Abiko, K.,
Konishi, I., 2024, Development of Endosalpingiosis in Patients with a History
of Breast Cancer. Georgian medical news, (355), 72-76.
[14]. Gecit, I., Aslan, M., Gunes, M., Pirincci, N., Esen,
R., Demir, H., Ceylan, K., 2012, Serum prolidase activity, oxidative stress,
and nitric oxide levels in patients with bladder cancer. Journal of cancer
research and clinical oncology, 138, 739-743. doi:10.1007/s00432-011-1136-4.
[15]. Aslan, M., Duzenli, U., Esen, R., Soyoral, Y. U.,
2017, Serum prolidase enzyme activity in obese subjects and its relationship
with oxidative stress markers. Clinica Chimica Acta, 473, 186-190. doi: 10.1016/j.cca.2017.08.039.
[16]. Kaba, M., Pirincci, N., Demir, H., Verep, S., 2024,
Serum prolidase activity, oxidative stress, and antioxidant enzyme levels in
patients with prostate cancer. In Urologic Oncology: Seminars and Original
Investigations, 42(4): 116-e9, doi: 10.1016/j.urolonc.2024.01.007.
[17]. Belli, S., Demir, H., Ozdemir, B., Demir, C., 2021,
Prolidase, Paraoxonase-1, Arylesterase Activity In Oral Squamous Cell
Carcinoma. Eastern Journal of Medicine, 26(1), doi:10.5505/ejm.2021.39358.
[18]. Kilic-Toprak, E., Toprak, I., Caliskan, S., Ozdemir, Y.,
Demirtas, O., Altintas, F., Kucukatay, V. 2019, Oxidative stress and
genotoxicity in pterygium: a systemic investigation. Eye & Contact Lens,
45(6), 399-404. doi:10.1097/ICL.0000000000000620.
[19]. Siegel, R. L., Miller, K. D., Jemal, A., 2019,
Cancer statistics, 2019. CA: a cancer
journal for clinicians, 69(1), 7-34. doi:10.3322/caac.21551.
[20]. Richters, A., Aben, K. K., Kiemeney, L. A., 2020, The
global burden of urinary bladder cancer: an update. World journal of
urology, 38(8), 1895-1904. doi:10.1007/s00345-019-02984-4.
[21]. Plouvier, S. D., Bonnal, J. L., Machuron, F., Colin,
P., Vankemmel, O., Leroy, X., Pasquier, D., 2020, Impact of age on bladder
cancer management practices: a general population study. Acta Oncologica,
59(4), 462-466. doi:10.1080/0284186X.2020.1723164.
[22]. Messing, E., Gee, J. R., Saltzstein, D. R., Kim, K.,
diSant'Agnese, A., Kolesar, J., Bailey, H., 2012, A phase 2 cancer
chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical
bladder cancer patients. Cancer prevention research, 5(4), 621-630. doi: 10.1158/1940-6207.CAPR-11-0455.
[23]. Kamińska, J., Dymicka-Piekarska, V., Tomaszewska, J.,
Matowicka-Karna, J., Koper-Lenkiewicz, O. M., 2020, Diagnostic utility of
protein to creatinine ratio (P/C ratio) in spot urine sample within routine
clinical practice. Critical reviews in clinical laboratory sciences,
57(5), 345-364. doi:10.1080/10408363.2020.1723487.
[24]. Feng, H., Deng, Z., Huang, Y., Liu, Z., Ruan, Y.,
Wang, T., Liu, J., 2023, A novel cuproptosis pattern and tumor immune
microenvironment characterization in urothelial carcinoma of the bladder. Frontiers
in Immunology, 14, 1219209. doi:10.3389/fimmu.2023.1219209.
[25]. Han, X., Stevens, J., Truesdale, K. P., Bradshaw, P.
T., Kucharska‐Newton, A., Prizment, A. E., Joshu, C. E., 2014, Body mass index
at early adulthood, subsequent weight change and cancer incidence and
mortality. International journal of cancer, 135(12), 2900-2909. doi:10.1002/ijc.28930.
[26]. Khanna, D., Khanna, S., Khanna, P., Kahar, P., Patel,
B. M., 2022, Obesity: a chronic low-grade inflammation and its markers. Cureus,
14(2).
doi:10.7759/cureus.22711.
[27]. Barsouk, A., Padala, S. A., Vakiti, A., Mohammed, A.,
Saginala, K., Thandra, K. C., Barsouk, A., 2020, Epidemiology, staging and
management of prostate cancer. Medical sciences, 8(3), 28. doi:10.3390/medsci8030028.
[28]. Suyanto, J., Sianipar, B. K., Sofais, D. A. R.,
Panduragan, S. L., 2024, Structured Training Program About Breast Self-Examination
Toward Awareness and Behavior Among Women in Bengkulu City, Indonesia. Public
Health of Indonesia, 10(3), 383-390. doi:10.36685/phi. v10i3.833.
[29]. Soria, J. C., Ohe, Y., Vansteenkiste, J.,
Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Ramalingam, S. S., 2018,
Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. New
England journal of medicine, 378(2), 113-125. doi: 10.1056/NEJMoa1713137.
[30]. Ma, W., Zhang, W., Shen, L., Liu, J., Yang, F.,
Maskey, N., Yao, X., 2021, Can smoking cause differences in urine microbiome in
male patients with bladder cancer? A retrospective study. Frontiers in
oncology, 11, 677605. doi:10.3389/fonc.2021.677605.
[31]. Skulberg, K. R., Hamid, S., Vaktskjold, A., 2019, Smoking among adolescent males at Pulau Weh, Indonesia. Public Health of Indonesia, 5(3):62–70. http://stikbar.org/ycabpublisher/index.php/PHI/index.